Surrey Clinical Research Centre Signs Five-Year Contract Renewal With OmniComm Systems


Leading Academic Research Centre Continues its Collaboration With OmniComm’s Promasys® EDC

Fort Lauderdale, FL, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Surrey Clinical Research Centre, a core human research resource within the Faculty of Health & Medical Sciences at University of Surrey in the United Kingdom, has signed a new five-year renewal contract to use Promasys EDC from OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology.

Surrey Clinical Research, an MHRA Phase I accredited facility with expertise in Phase I, first-in-human, through to Phase IV, has used Promasys since 2014, and the new agreement extends that commitment for an additional five-year period from 2019 to 2024. Surrey CRC is able to advise and execute the complete clinical trials process from start to finish, including protocol design and development, oversight of all regulatory applications, set-up, management and conduct, as well as data management, data analysis and reporting from single-site to global multi-center trials.

The enhanced features and functionality of Promasys 7.4 include improvements to the Lab Connector, Lab Review Module, Sample Tracking, Event Coding and Electronic Signatures — all of which were instrumental in securing the new agreement with Surrey. In addition, PRO workflow capabilities were an added bonus, as Surrey is looking to incorporate patient-reported outcomes in upcoming studies.

“The Surrey Clinical Research Centre is excited to continue and develop their well-established working relationship with OmniComm. The Promasys EDC system has been an excellent asset for both our clinical trial and academic research projects,” said Vikki Revell, Ph.D., head of Research and Study Management at Surrey Clinical Research Centre.

Promasys is an integrated clinical data management and EDC system that brings industry standard quality and efficiency to data collection and data management in clinical trials. Built on a history of innovation spanning almost 30 years and utilized in more than 1,000 clinical trials around the globe, Promasys has become the data management and EDC solution of choice for many of the world’s leading academic, medical research and life science organizations.

“We’re delighted to have earned the trust and renewed business commitment from Surrey Clinical Research Centre, especially given that it is one of the most prestigious research institutes in the United Kingdom,” said Kuno van der Post, Ph.D., chief commercial officer of OmniComm.

About Surrey Clinical Research Centre
Surrey CRC has a prestigious track record of over 15 years’ experience undertaking clinical trials in both participant and patient populations from Phase I, first-in-human, through to Phase IV. In addition to working with leading pharmaceutical companies,  Surrey CRC collaborates with small biotech organisations, charitable organisations, basic science and clinical academic colleagues on a range of studies including CTIMP, medical device and interventional studies. Surrey CRC has particular expertise in sleep, psychopharmacology, circadian rhythms, chronopharmacology, oncology, immunology, vaccines and early phase studies in healthy participants. Please visit https://crc.surrey.ac.uk/ for more information.

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information, and follow OmniComm on Twitter: @OmniCommSystems, on LinkedIn: @OmniComm Systems and Facebook: @OmniComm Systems, Inc.

Trademarks
OmniComm, Promasys, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.



            

Coordonnées